Tradestie Institutional Equity Comparison Engine

TLPH vs ACCL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACCL Overall Edge

ACCL Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ACCL (ACCL) driven by superior Growth & Margin, Momentum & Technical while TLPH counters with relative strength in Valuation, Options & Structure. Fundamentally, TLPH trades at 1.0x Forward P/E with -1474700.0% operating margin (+0.0% YoY revenue) versus ACCL at N/M Forward P/E and 4.5% operating margin (+11.3% YoY). In options structure, TLPH sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against ACCL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner TLPH
TLPH 1.0x vs ACCL N/M Fwd P/E
Growth & Margin Winner ACCL
Op Margin -1474700.0% vs 4.5% ยท YoY +0.0% vs +11.3%
Momentum & Technical Winner ACCL
1Y -18.0% vs -42.4% ยท 52W Pos 20% vs 30%
Options & Structure Winner TLPH
UNCLASSIFIED (100th %ile IV) vs UNCLASSIFIED (N/A IV)
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
1M Return -20.29%
1Y Return -18.01%
Forward P/E 1.0x
Unified AI Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
ACCL US Equity
ACCL
Institutional Equity
$2.36
-0.84% 1D
Market Cap $33.5M
1M Return -12.26%
1Y Return -42.44%
Forward P/E N/M
Unified AI Score
63.4 / 100 BUY
Tech 68.0 Fund 58.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TLPH -18.01% ACCL -42.44% Spread: +25.66 pp (TLPH Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
TLPH TTM Op. Margin: -1474700.0% ACCL TTM Op. Margin: 4.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLPH vs ACCL. Trailing 12-month operating profitability (TLPH -1474700.0% vs ACCL 4.5%) and valuation multiples (TLPH 1.0x vs ACCL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TLPH (4) vs ACCL (6)
Institutional Metric TLPH ACCL Criterion Row Winner
Market Capitalization Scale $53.7M $33.5M Larger Scale TLPH
Trailing P/E Ratio Valuation 1.0x 120.0x Lower Multiple TLPH
Forward P/E Ratio Valuation 1.0x N/M Lower Multiple TLPH
Revenue Growth (YoY) Growth +0.0% +11.3% Higher Growth ACCL
Operating Margin (TTM) Profitability -1474700.0% 4.5% Higher Margin ACCL
Net Profit Margin Profitability 0.0% 5.5% Higher Margin ACCL
Return on Equity (ROE) Capital Efficiency -143.4% 7.0% Higher ROE ACCL
52-Week Range Position Momentum 20% ($1โ€“$2) 30% ($1โ€“$5) Stronger Trend ACCL
Beta / 30D Volatility Risk Regime 1.11ฮฒ ยท 58% Vol -0.20ฮฒ ยท 60% Vol Lower Realized Risk TLPH
Unified Institutional Score Composite Signal 37.1 / 100 (SELL) 63.4 / 100 (BUY) Higher Composite ACCL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TLPH vs ACCL Buy Guide
TLPH UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live TLPH Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACCL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ACCL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TLPH nor ACCL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.